D
Daniel Adamsadded this to Biotechnology
Amgen, Novartis aim for big, crowded migraine market after new drug data

Amgen, Novartis aim for big, crowded migraine market after new drug data

Reuters - by Divya Grover in Bengaluru and John Miller in Zurich

(Reuters) - Amgen Inc and Novartis said late on Wednesday that episodic migraine sufferers reported fewer debilitating headaches per month after using the companies’ investigational drug erenumab, compared to trial participants who got a placebo. An Amgen sign is seen at the company's office in …

View on reuters.com